The global 3D bioprinted human tissue market is projected to grow from $2.5 billion in 2025 to $3.9 billion by 2035 at a 4.6% CAGR, driven by regenerative medicine demand and advances in hybrid hydrogel materials for tissue engineering.
AstraZeneca's CALQUENCE received FDA approval as the first all-oral, fixed-duration regimen for chronic lymphocytic leukemia, while the EMA validated the marketing authorization application for ENHERTU in HER2-positive breast cancer treatment.
The FDA approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration regimen for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, based on Phase 3 AMPLIFY trial results.
The FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia, based on phase III AMPLIFY trial results showing 35% reduction in disease progression or death risk versus chemoimmunotherapy.
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06251232 |
Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity |
NOT_YET_RECRUITING | PHASE2 |
| NCT05501899 |
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia |
RECRUITING | EARLY_PHASE1 |
| NCT04635111 |
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
RECRUITING | |
| NCT03833297 |
Monitoring the HePAtological TOXicity of Drugs (HePATOX) |
COMPLETED | |
| NCT03602274 |
APAP Hepatotoxicity After Therapeutic Doses |
UNKNOWN | |
| NCT02076685 |
NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis |
UNKNOWN | NA |
| NCT00768716 |
Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics |
COMPLETED | PHASE4 |
| NCT00728546 |
NAT2 in Re-challenge of INH in Patients With Hepatitis |
UNKNOWN | PHASE4 |
| NCT00137059 |
Acetaminophen-induced Hepatotoxicity in Chronic Alcohol Abusers |
COMPLETED | NA |
